Baker Bros. Advisors Adds $2M in CytomX Therapeutics, Inc. ($CTMX)
Key Points
- Baker Bros. Advisors changed its CytomX Therapeutics, Inc. ($CTMX) stake by 17.1% last quarter, boosting to 4,975,826 shares worth $14.98 million.
- Wall Street's consensus rating on $CTMX is Strong Buy and an average price target of $12.50.
- $CTMX last traded around $3.01.
Baker Bros. Advisors increased its position in CytomX Therapeutics, Inc. ($CTMX) by 17.1% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,975,826 shares of CytomX Therapeutics, Inc. after buying 725,000 shares during the quarter. Baker Bros. Advisors's holdings in CytomX Therapeutics, Inc. were worth $14.98 million as of its most recent filing.
CytomX Therapeutics, Inc. ($CTMX) Stock
CytomX Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.